Manulife (Manufacturers Life Insurance)’s Enliven Therapeutics ELVN Stock Holding History

Manulife (Manufacturers Life Insurance)’s Portfolio ELVN Stock Details ELVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$919K	Buy	23,441 +4,105	+21%	+$114K	﹤0.01%	1871
2025 Q4	$298K	Sell	19,336 -24,668	-56%	-$491K	﹤0.01%	2362
2025 Q3	$901K	Sell	44,004 -147	-0.3%	-$2.96K	﹤0.01%	1910
2025 Q2	$886K	Buy	44,151 +31,257	+242%	+$592K	﹤0.01%	1879
2025 Q1	$254K	Sell	12,894 -3,942	-23%	-$84.8K	﹤0.01%	2395
2024 Q4	$379K	Sell	16,836 -446	-3%	-$11.6K	﹤0.01%	2360
2024 Q3	$441K	Buy	17,282 +3,518	+26%	+$81.5K	﹤0.01%	2335
2024 Q2	$322K	Buy	+13,764	New	+$290K	﹤0.01%	2390
2024 Q1	–	Sell	-10,095	Closed	-$140K	–	2959
2023 Q4	$140K	Buy	+10,095	New	+$124K	﹤0.01%	2729

Other funds holding ELVN

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Manulife (Manufacturers Life Insurance)'s ELVN Position: Q1 2026 in Review

Manulife (Manufacturers Life Insurance) increased its Enliven Therapeutics (ELVN) stake by 21% in Q1 2026, buying an estimated $114K and bringing the position to 23,441 shares worth $919K. The position accounts for ﹤0.01% of the portfolio, ranked #1871.

Manulife (Manufacturers Life Insurance) first reported a position in ELVN in Q4 2023 and has held it in 9 quarters since. 170 funds tracked by Wall St. Rank hold ELVN as of Q1 2026.

Manulife (Manufacturers Life Insurance) held 23,441 shares of Enliven Therapeutics worth $919K as of Q1 2026.
Manulife (Manufacturers Life Insurance) bought 4,105 Enliven Therapeutics shares in Q1 2026, an estimated $114K.
Enliven Therapeutics made up ﹤0.01% of Manulife (Manufacturers Life Insurance)'s portfolio in Q1 2026, its #1871 holding.
Manulife (Manufacturers Life Insurance) first reported a position in Enliven Therapeutics in Q4 2023 and has held it in 9 quarters since.
170 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q1 2026.

Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q1 2026, filed 15 May 2026.